IMMUNOVANT, INC.— Sankey Diagram

Annual mode · period ending 2025-12-31 · SEC EDGAR

FY2024 - Q4(Jan 24 · Feb 24 · Mar 24)
Total Assets
$1.05B
↑+150.0% +$631Mvs FY2024
Total Liabilities
$66M
↓-3.0% -$2Mvs FY2024
Equity
$986M
↑+179.7% +$634Mvs FY2024
Cash
$995M
↑+165.4% +$620Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the annual mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025FY2024
Total Assets$1.05B$421M
Current Assets$1.04B$413M
Cash$995M$375M
ST Investments$0$0
Receivables$2M$2M
Inventory$0$0
Other Current$47M$36M
Non-Current Assets$9M$8M
PPE$531K$752K
Goodwill$0$0
Intangibles$0$0
Investments$0$0
Other Non-Current$9M$8M
Total Liab+Eq$1.05B$421M
Current Liab.$66M$68M
Accounts Payable$9M$20M
Short-Term Debt$0$0
Deferred Revenue$0$0
Other CL$58M$48M
Non-Current Liab.$0$0
Long-Term Debt$0$0
Other LT Liab.$0$0
Equity$986M$353M
Retained Earnings$1.60B$1.13B
Other Equity$0$0

QuarterCharts · SEC EDGAR data · IMVT · Comparing FY2025 vs FY2024